KALA BIO, Inc.
$0.63 +$0.02 (+3.92%) 1D After hoursKey Metrics
The Story So Far
LAST 6 MONTHS PRIMARY SOURCES ONLY-
Jul 23
From its Jan 29 high, the share price fell 98%.
Peak close $27.00 on Jan 29; trough close $0.61 on Jul 23. The drawdown is the fact — the chapters around it are the context.
RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -98% -
Jul 22
Offering paper hit the record (Form 424B5).
424B5 - KALA BIO, Inc. (0001479419) (Filer)
RECEIPT: SEC FORM 424B5, TIMESTAMPED -
Jul 16
Money rotated out of high-beta cohorts market-wide.
High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.
RECEIPT: ROTATION GAUGE, LIVE -
Jun 18
The stock moved +26.9% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, Jun 18 -
May 7
The stock moved -27.8% in a single session.
Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.
RECEIPT: DAILY BAR, May 7
The story updates itself as events post · The wolf reports; you decide
Snapshot
About KALA BIO, Inc.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye.
Wolf Grade COMING SOON
The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.